These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 1903100)

  • 1. Pharmacokinetics of didanosine in patients with acquired immunodeficiency syndrome or acquired immunodeficiency syndrome-related complex.
    Knupp CA; Shyu WC; Dolin R; Valentine FT; McLaren C; Martin RR; Pittman KA; Barbhaiya RH
    Clin Pharmacol Ther; 1991 May; 49(5):523-35. PubMed ID: 1903100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine in patients with severe human immunodeficiency virus infection.
    Hartman NR; Yarchoan R; Pluda JM; Thomas RV; Marczyk KS; Broder S; Johns DG
    Clin Pharmacol Ther; 1990 May; 47(5):647-54. PubMed ID: 2111751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetic analysis of didanosine (2',3'-dideoxyinosine) plasma concentrations obtained in phase I clinical trials in patients with AIDS or AIDS-related complex.
    Pai SM; Shukla UA; Grasela TH; Knupp CA; Dolin R; Valentine FT; McLaren C; Liebman HA; Martin RR; Pittman KA
    J Clin Pharmacol; 1992 Mar; 32(3):242-7. PubMed ID: 1564128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relation between plasma concentrations of didanosine and markers of antiviral efficacy in adults with AIDS or AIDS-related complex.
    Beltangady M; Knupp CA; Gustafson N; Barbhaiya RH; Dolin R; Seidlin M; Cooley TP; Rozencweig M
    Clin Infect Dis; 1993 Feb; 16 Suppl 1():S26-31. PubMed ID: 8093845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of 2',3'-dideoxyinosine in patients with severe human immunodeficiency infection. II. The effects of different oral formulations and the presence of other medications.
    Hartman NR; Yarchoan R; Pluda JM; Thomas RV; Wyvill KM; Flora KP; Broder S; Johns DG
    Clin Pharmacol Ther; 1991 Sep; 50(3):278-85. PubMed ID: 1914362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A phase I trial.
    Lambert JS; Seidlin M; Reichman RC; Plank CS; Laverty M; Morse GD; Knupp C; McLaren C; Pettinelli C; Valentine FT
    N Engl J Med; 1990 May; 322(19):1333-40. PubMed ID: 2139173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Substitution of didanosine sachets by chewable tablets: a pharmacokinetic study in patients with AIDS.
    Burger D; Meenhorst P; Mulder J; Henrichs J; Frissen J; Kroon F; ten Napel C; Koks K; Bult A; Beijnen J
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Oct; 10(2):163-8. PubMed ID: 7552480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of bioavailability on determination of the maximal tolerated dose of 2',3'-dideoxyinosine in phase I trials.
    Drusano GL; Yuen GJ; Morse G; Cooley TP; Seidlin M; Lambert JS; Liebman HA; Valentine FT; Dolin R
    Antimicrob Agents Chemother; 1992 Jun; 36(6):1280-3. PubMed ID: 1416828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The National Cancer Institute phase I study of 2',3'-dideoxyinosine administration in adults with AIDS or AIDS-related complex: analysis of activity and toxicity profiles.
    Yarchoan R; Mitsuya H; Pluda JM; Marczyk KS; Thomas RV; Hartman NR; Brouwers P; Perno CF; Allain JP; Johns DG
    Rev Infect Dis; 1990; 12 Suppl 5():S522-33. PubMed ID: 1974724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disposition of didanosine in HIV-seropositive patients with normal renal function or chronic renal failure: influence of hemodialysis and continuous ambulatory peritoneal dialysis.
    Knupp CA; Hak LJ; Coakley DF; Falk RJ; Wagner BE; Raasch RH; van der Horst CM; Kaul S; Barbhaiya RH; Dukes GE
    Clin Pharmacol Ther; 1996 Nov; 60(5):535-42. PubMed ID: 8941026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of potential risk factors associated with the development of pancreatitis in phase I patients with AIDS or AIDS-related complex receiving didanosine.
    Grasela TH; Walawander CA; Beltangady M; Knupp CA; Martin RR; Dunkle LM; Barbhaiya RH; Pittman KA; Dolin R; Valentine FT
    J Infect Dis; 1994 Jun; 169(6):1250-5. PubMed ID: 8195601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I dose-escalation pharmacokinetics of AZT-P-ddI (IVX-E-59) in patients with human immunodeficiency virus.
    Zhou XJ; Squires K; Pan-Zhou XR; Bernhard S; Agrofoglio L; Kirk M; Duchin KL; Sommadossi JP
    J Clin Pharmacol; 1997 Mar; 37(3):201-13. PubMed ID: 9089422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of 2'-3'-dideoxyinosine administered orally twice daily to patients with AIDS or AIDS-related complex and hematologic intolerance to zidovudine.
    Connolly KJ; Allan JD; Fitch H; Jackson-Pope L; McLaren C; Canetta R; Groopman JE
    Am J Med; 1991 Nov; 91(5):471-8. PubMed ID: 1659189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of time of food administration on the bioavailability of didanosine from a chewable tablet formulation.
    Knupp CA; Milbrath R; Barbhaiya RH
    J Clin Pharmacol; 1993 Jun; 33(6):568-73. PubMed ID: 8366182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic-interaction study of didanosine and ranitidine in patients seropositive for human immunodeficiency virus.
    Knupp CA; Graziano FM; Dixon RM; Barbhaiya RH
    Antimicrob Agents Chemother; 1992 Oct; 36(10):2075-9. PubMed ID: 1444287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of high-dose oral ganciclovir on didanosine disposition in human immunodeficiency virus (HIV)-positive patients.
    Jung D; Griffy K; Dorr A; Raschke R; Tarnowski TL; Hulse J; Kates RE
    J Clin Pharmacol; 1998 Nov; 38(11):1057-62. PubMed ID: 9824788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in patients with the acquired immunodeficiency syndrome.
    Barry M; Howe JL; Ormesher S; Back DJ; Breckenridge AM; Bergin C; Mulcahy F; Beeching N; Nye F
    Br J Clin Pharmacol; 1994 May; 37(5):421-6. PubMed ID: 8054247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Food-induced reduction in bioavailability of didanosine.
    Shyu WC; Knupp CA; Pittman KA; Dunkle L; Barbhaiya RH
    Clin Pharmacol Ther; 1991 Nov; 50(5 Pt 1):503-7. PubMed ID: 1934863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetics of stavudine (d4T) in patients with AIDS or advanced AIDS-related complex.
    Horton CM; Dudley MN; Kaul S; Mayer KH; Squires K; Dunkle L; Anderson R
    Antimicrob Agents Chemother; 1995 Oct; 39(10):2309-15. PubMed ID: 8619587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using Gaussian-like input rate function in the two-compartment model. Formulation and application to analysis of didanosine plasma concentration in two Japanese hemophiliacs.
    Tatsunami S; Sako K; Kuwabara R; Yamada K
    Int J Clin Pharmacol Res; 1998; 18(3):129-35. PubMed ID: 9825269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.